Oncogenic tyrosine kinases

Cellular and Molecular Life Sciences

Volumn 61, Issue 23, 2004, Pages 2895-2896

  Gambacorti Passerini, C ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IMATINIB; PROTEIN TYROSINE KINASE;

CANCER RESISTANCE; CARCINOGENESIS; CELL TRANSFORMATION; GENE DELETION; GENE TARGETING; LUNG NON SMALL CELL CANCER; MISSENSE MUTATION; ONCOGENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SHORT SURVEY; SIGNAL TRANSDUCTION;

ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MUTATION; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES;

EID: 12144279856     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-4270-1     Document Type: Short Survey

References (4)

1. Manning G., Whyte D. B., Martinez R., Hunter T. and Sudarsanaman S. (2002) The protein kinase complement of the human genome. Science 298: 1912-1934
2. Noble M., Endicott J. A. and Johnson L. N. (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303: 1800-1805
3. Paez G., Jaenne P. A., Lee J. C., Tracy S., Greulich H., Gabiel S. et al. (2004) EGFR mutations in lung cancer: correlation with clinical responses to Gefitinib therapy. Science 304: 1458-1461
4. Lynch T. J., Bell D. W., Sordella R., Gurubhagavatula S., Okimoto R. A., Brannigan B. W. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. NEJM, 350: 2129-2139